Mike DeProspero
Vice President
Mike DeProspero is a Vice President in PMCF’s Chicago office with ten years of experience in financial accounting and M&A advisory. He provides transaction support across sell-side, buy-side, and capital raising engagements, with a focus on financial and strategic analysis, valuation, industry research, due diligence, and the development of client marketing materials.
Before joining PMCF, Mike was a Financial Due Diligence Advisor at PwC, where he specialized in the healthcare, technology, manufacturing, and retail sectors. He holds a BS in accounting, finance, and business with a minor in analytical consulting from the Mitch Daniels School of Business at Purdue University. Mike is a licensed Certified Public Accountant in the state of Illinois and a licensed securities representative holding his Series 82 and 63 registrations. He is currently pursuing an MBA from the Booth School of Business at the University of Chicago.
Transaction Experience
PMCF Advises Metropolitan Alloys Corporation and Aluminum Recovery Technologies on Their Sale to Metal Conversions
PMCF Advises Niowave on its Non-Dilutive Financing from Novartis
PMCF Advises The Grote Company Family of Brands in its Transaction with BBH Capital Partners Private Equity
PMCF Advises Pro-Vision in its Sale to Vance Street Capital
PMCF Advises Besse Forest Products Group in its Sale to The Hoffmann Family of Companies
PMCF Advises Tire Wholesalers in its sale to Turbo Wholesale Tires, a portfolio company of Kingswood Capital Management
PMCF Advises The Partner Companies, LLC in its Acquisition of UPG Company, LLC
PMCF Advises Instrumart In Its Sale to Flow Control Group, a KKR Portfolio Company
Publications
Medical Technology M&A Pulse – Q1 2026
M&A activity slowed in Q1 2026, with deal volume hitting a multi‑year low, reflecting a shift toward fewer, higher‑conviction transactions.
Medical Technology M&A Pulse – Q4 2025
M&A activity in the Medical Technology sector stayed on par with the previous two quarters, with 105 announced transactions. Volume is significantly lower than the same quarter last year, with 135 deals in Q4 2024.
2026 Medtech M&A Outlook Strengthens as Buyers Prioritize Innovation and Resilience
Medtech is entering 2026 with a healthier M&A environment supported by improved financing conditions, resilient sector performance, and a more straightforward path for strategic buyers and private equity.
Medical Technology M&A Pulse – Q3 2025
M&A activity in the Medical Technology sector remained subdued in Q3 2025 at 102 announced transactions, significantly below the 165 deals recorded in Q3 2024.
Tariffs & Workforce Talent: Two Factors Shaping Healthcare M&A in 2025
Tariffs and staffing stability remain key factors shaping healthcare and MedTech M&A in 2025.